EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Enhancing triapine treatment: strategies for dose optimization and methemoglobin level mitigation

Heekyung Lee, Allison Dunn, Sarah E Taylor, Aman Chauhan, S Percy Ivy, Jogarao Gobburu, Jan H Beumer

Cancer Chemotherapy and Pharmacology · 20.05.2026 · 96 (1)

DOI: 10.1007/s00280-026-04898-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 20.05.2026. Verfasst von Heekyung Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Translational Medicine, University of Maryland School of Pharmacy, 20 North Pine Street, Baltimore, MD, 21201, USA. Hauptthemen laut MEDLINE: Methemoglobin, Models, Biological, Pyridines, Thiosemicarbazones. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Triapine is a potent small-molecule ribonucleotide reductase inhibitor investigated in combination with radiation and/or chemotherapy for the treatment of advanced stage solid cancers. The aim of this study is to develop a population pharmacokinetic-pharmacodynamic (PK/PD) model for triapine to describe the PK parameters, the effect of smoking on exposure, and the relationship between methemoglobin concentrations and exposure.

Methods

A total of 36 patients with advanced stage cervical or neuroendocrine cancers from two phase I studies were included in the population PK/PD model building. Triapine and methemoblogin plasma concentrations were sampled over an 8-hr or 24-hour period. Data were analyzed by a nonlinear mixed-effects modelling approach. Simulations were performed to optimize the dosing strategy for oral triapine.

Results

A two-compartment model with two-transit compartment Erlang absorption and first-order elimination best described the PK of triapine, and an effect compartment model best described the PD effect of triapine on methemoglobin concentrations. The final model described triapine PK/PD well, and a 38% increase in triapine clearance was estimated due to smoking. Simulations suggest that dose adjustments may be necessary, as increasing the oral dose for smokers from 100 to 125 mg resulted in exposures matching those observed in nonsmokers.

Conclusion

This study provides a quantitative model characterizing the relationship between triapine exposure and methemoglobin concentrations. The developed PK/PD model can be used to optimize the dosing regimen for oral triapine, illustrating how population PK/PD modeling can inform decision-making throughout the triapine drug development lifecycle.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethemoglobinModels, BiologicalPyridinesThiosemicarbazonesAgedFemaleHumansMaleMiddle AgedDose-Response Relationship, DrugSmokingClinical Trials, Phase I as Topic

Stichwörter der Autor:innen

MethemoglobinPharmacodynamicsPharmacokineticsRadiosensitizerTriapine

Substanzen

3-aminopyridine-2-carboxaldehyde thiosemicarbazoneMethemoglobinPyridinesThiosemicarbazones

Autor:innen und Institutionen

  • Center for Translational Medicine, University of Maryland School of Pharmacy, 20 North Pine Street, Baltimore, MD, 21201, USA.
  • Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
  • Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
  • Cancer Therapeutics Program, UPMC Hillman Cancer Centre, Pittsburgh, PA, USA. jan.beumer@jhu.edu.
  • Department of Oncology, Johns Hopkins University School of Medicine and Johns Hopkins Sidney Kimmel Cancer Center, 1650 Orleans St, Room 1M52, Baltimore, MD, 21287, USA. jan.beumer@jhu.edu.

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Lee, H., Dunn, A., Taylor, S. E., Chauhan, A., Ivy, S. P., Gobburu, J., & Beumer, J. H. (2026). Enhancing triapine treatment: strategies for dose optimization and methemoglobin level mitigation. Cancer Chemotherapy and Pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04898-6

Vancouver

Lee H, Dunn A, Taylor SE, Chauhan A, Ivy SP, Gobburu J, et al. Enhancing triapine treatment: strategies for dose optimization and methemoglobin level mitigation. Cancer Chemotherapy and Pharmacology. 2026;96(1). doi:10.1007/s00280-026-04898-6

BibTeX
@article{Lee2026,
  author = {Lee, Heekyung and Dunn, Allison and Taylor, Sarah E and Chauhan, Aman and Ivy, S Percy and Gobburu, Jogarao and Beumer, Jan H},
  title = {Enhancing triapine treatment: strategies for dose optimization and methemoglobin level mitigation},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2026},
  volume = {96},
  number = {1},
  doi = {10.1007/s00280-026-04898-6}
}
Kostenlos starten →